PremiumThe FlyPepGen to discontinue DMD programs after PGN-EDO51 did not achieve target PepGen price target lowered to $8 from $14 at H.C. Wainwright PepGen Inc.’s Strategic Shift Amidst DMD Program Discontinuation and Competitive Challenges PremiumThe FlyPepGen price target lowered to $14 from $16 at H.C. Wainwright PepGen Inc. Expands Board with New Appointments PepGen names two new directors to board PremiumCompany AnnouncementsPepGen Inc. Reports Positive Trial Results and Financials Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges Apple to invest $500B in U.S., Domino’s reports downbeat Q4: Morning Buzz 
